news
UCSF Launches 3,000-Person Study Tracking Real-World Psychedelic Use
UCSF neuroscientists led by Robin Carhart-Harris secured an $8.5 million federal grant to launch CANOPY, a study tracking 3,000 people taking psychedelics in everyday settings. The researchers will monitor participants using wearable sensors, remote surveys, and brain scans to see how these substances perform outside hospital walls. It marks a major shift toward studying real-world nervous system responses rather than manicured clinical trials.
UCSF neuroscientists led by Robin Carhart-Harris secured an $8.5 million federal grant to launch CANOPY, a study tracking 3,000 people taking psychedelics in everyday settings. The researchers will monitor participants using wearable sensors, remote surveys, and brain scans to see how these substances perform outside hospital walls. It marks a major shift toward studying real-world nervous system responses rather than manicured clinical trials.
The architecture take
Clinical trials spent years trying to sterilize psychedelic therapy inside beige hospital rooms with eye shades and soft blankets. I used to think that rigid clinical setting was the only way regulators would take these compounds seriously, but I was wrong. Most people take psilocybin in living rooms, cabins, and backyards where sensory input is completely uncontrolled. Robin Carhart-Harris and his UCSF team are finally studying where people actually trip. By pairing self-reports with wearable sensors, the study tracks what happens to heart rate variability, sleep stages, and autonomic tone across 3,000 sessions in the wild. I suspect the most useful data won't come from the peak experience, but from the forty-eight hours after a dose. Lab trials routinely ignore the crash that hits when serotonin receptors downregulate and sleep quality tanks. I want to see if continuous biometric tracking can spot that rebound before someone slides into an unassisted depressive slump. Messy data beats sanitized fiction.